By Counterforce Health Team in Enhertu (fam-trastuzumab deruxtecan-nxki) —

How to Get Enhertu (fam-trastuzumab deruxtecan-nxki) Covered by Aetna CVS Health in Washington: Complete PA Guide and Appeals Process

Answer Box: Getting Enhertu Covered in Washington

Enhertu (fam-trastuzumab deruxtecan-nxki) requires prior authorization from Aetna CVS Health for all FDA-approved indications. Approval requires documented HER2 status (IHC 3+, ISH+, HER2-low 1-2+, or HER2-mutant), prior therapy failure, board-certified oncologist prescriber, and ILD monitoring plan. Submit via Aetna Enhertu Precertification Form GR-69531 to fax 888-267-3277. If denied, Washington residents have 180 days to appeal internally, then can request external review through an Independent Review Organization (IRO) via the Washington Office of Insurance Commissioner. First step today: Contact your oncologist for HER2 pathology report and prior treatment records.

Table of Contents

  1. Is Enhertu Covered by Aetna CVS Health?
  2. Prior Authorization Process
  3. Timing and Urgency
  4. Clinical Criteria Requirements
  5. Cost and Specialty Pharmacy
  6. Common Denials and Appeals in Washington
  7. Renewal Requirements
  8. CVS Specialty Pharmacy Process
  9. Troubleshooting Common Issues
  10. Frequently Asked Questions

Is Enhertu Covered by Aetna CVS Health?

Enhertu is classified as a non-formulary specialty medication requiring prior authorization for all FDA-approved indications, including:

  • HER2-positive breast cancer (unresectable/metastatic, after prior anti-HER2 therapy)
  • HER2-low breast cancer (unresectable/metastatic, after prior chemotherapy)
  • HER2-mutant non-small cell lung cancer (after prior platinum-based therapy)
  • HER2-positive gastric/gastroesophageal junction cancer (after prior trastuzumab-based therapy)

All Aetna CVS Health commercial plans in Washington follow the same Clinical Policy Bulletin 0966 for coverage criteria.

Prior Authorization Process

Step-by-Step: Fastest Path to Approval

  1. Gather Required Documents (Patient/Clinic)
    • HER2 pathology report with IHC/ISH results from CLIA-certified lab
    • Complete prior therapy records with dates, doses, outcomes
    • Current staging and performance status
    • Patient weight and BSA calculations
    • ICD-10 diagnosis codes
  2. Complete PA Form (Oncologist)
  3. Submit Application (Clinic Staff)
    • Fastest: Availity portal or CoverMyMeds.com
    • Fax: 888-267-3277 (Enhertu dedicated line)
    • Phone: 866-752-7021 for urgent cases
    • Submit 2+ weeks before planned treatment start
  4. Track Decision (Patient/Clinic)
    • Standard: 30-45 business days
    • Expedited: 72 hours with physician attestation of urgency
    • 95% of complete applications approved within 24 hours

Timing and Urgency

Request Type Timeline When to Use
Standard PA 30-45 business days Newly diagnosed, stable disease
Expedited PA 72 hours Disease progression, urgent clinical need
Appeal (Internal) 60 business days After PA denial
External Review 30 days After internal appeal denial
Tip: Submit PA requests at least 2 weeks before your planned infusion date to avoid treatment delays.

Clinical Criteria Requirements

Coverage at a Glance

Requirement What It Means Where to Find It
HER2 Testing IHC 3+, ISH+, IHC 1-2+, or mutation Original pathology report
Prior Therapy Documented failure/intolerance Treatment records with outcomes
Prescriber Board-certified oncologist NPI and DEA verification
ILD Monitoring Baseline assessment and plan Chest CT, PFTs, monitoring schedule
Site of Care In-network infusion center Provider directory verification

Medical Necessity Letter Checklist

Your oncologist's letter should include:

  • Diagnosis: ICD-10 codes with staging
  • HER2 Status: Specific test results (e.g., "HER2 3+ by IHC")
  • Prior Treatments: Drug names, dates, duration, reason for discontinuation
  • Clinical Rationale: Why Enhertu is appropriate now
  • Guidelines: Reference to FDA label and NCCN guidelines
  • Safety Plan: ILD monitoring with baseline imaging

Cost and Specialty Pharmacy

Enhertu is dispensed exclusively through CVS Specialty Pharmacy after PA approval. The medication uses J-code J9358 for buy-and-bill outpatient infusion.

Patient Cost Options

  • Insurance Coverage: Copay/coinsurance per your plan benefits
  • Manufacturer Support: Enhertu Co-pay Program (eligibility restrictions apply)
  • Foundation Grants: Patient Advocate Foundation, CancerCare (verify current programs)

Common Denials and Appeals in Washington

Top Denial Reasons and Solutions

Denial Reason How to Fix
Missing HER2 Status Submit complete pathology report with IHC/ISH methodology
Insufficient Prior Therapy Provide detailed treatment timeline with specific outcomes
No ILD Monitoring Plan Include baseline chest CT and respiratory monitoring schedule
Non-Network Site Verify infusion center or request network exception
Non-Formulary Status Request formulary exception with medical necessity

Washington State Appeals Process

Internal Appeals (Aetna):

  • Deadline: 180 days from denial notice
  • Submit: Via member portal, phone (1-800-872-3862), or mail
  • Timeline: 60 business days for standard, 72 hours for expedited

External Review (Washington IRO):

  • When: After internal appeal denial
  • Deadline: 180 days from final internal denial
  • Process: Contact Washington Office of Insurance Commissioner at 1-800-562-6900
  • Timeline: 30 days for standard, 72 hours for expedited
  • Outcome: IRO decision is binding on Aetna
From our advocates: We've seen several Washington patients successfully overturn Enhertu denials through external review when the initial denial cited "experimental" status despite clear FDA approval for their specific indication. The key was submitting the complete FDA label and NCCN guideline excerpts showing standard-of-care status.

When navigating complex appeals like these, Counterforce Health helps patients and clinicians turn insurance denials into targeted, evidence-backed appeals by analyzing denial letters and crafting point-by-point rebuttals aligned to each plan's specific policies.

Renewal Requirements

Prior authorizations typically expire after 12 months. Renewal requires:

  • Updated staging and response assessment
  • Continued medical necessity documentation
  • Any new safety monitoring results
  • Confirmation of ongoing HER2-positive status if re-biopsied

Submit renewal requests 30-60 days before expiration to avoid treatment interruption.

CVS Specialty Pharmacy Process

After PA approval, you must enroll with CVS Specialty:

  1. Call: 1-800-237-2767 within 3-5 days of approval
  2. Provide: Demographics, insurance cards, prescriber details, infusion site address
  3. Coordination: CVS handles delivery 2-3 days before infusion
  4. Transfer: Automatic from other pharmacies if needed

Use the CVS Oncology Infused Medications Enrollment Form for faster processing.

Troubleshooting Common Issues

Portal Access Problems:

  • Reset password through Aetna member portal
  • Call member services: 1-800-872-3862
  • Use provider portal if you're clinic staff

Missing Forms:

Delayed Decisions:

  • Standard PAs taking >45 days: Call 866-752-7021
  • Missing information requests: Respond within 14 days to avoid denial

Frequently Asked Questions

Q: How long does Aetna CVS Health PA take in Washington? A: Standard requests take 30-45 business days, but 95% of complete applications are approved within 24 hours. Expedited requests for urgent cases are processed within 72 hours.

Q: What if Enhertu is non-formulary on my plan? A: Request a formulary exception by demonstrating that formulary alternatives are less effective or cause adverse effects. Include medical necessity documentation from your oncologist.

Q: Can I request an expedited appeal in Washington? A: Yes, if treatment delay would seriously jeopardize your health. Both internal appeals and external IRO reviews offer expedited options (72 hours).

Q: Does step therapy apply if I failed treatments outside Washington? A: Yes, Aetna recognizes prior therapy failures regardless of where treatment occurred. Include complete records from all providers.

Q: What happens if my external review is denied? A: IRO decisions are binding, but you can contact the Washington Office of Insurance Commissioner for guidance on any procedural concerns or file a complaint if you believe the process was mishandled.

Q: Do I need a referral to an oncologist for Enhertu PA? A: Requirements vary by plan. Check your Summary of Benefits or call member services to confirm referral requirements for specialty oncology care.

When dealing with complex prior authorization challenges, Counterforce Health specializes in helping patients and providers navigate insurance denials by creating evidence-backed appeals tailored to each payer's specific requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Coverage decisions depend on your specific plan benefits and clinical circumstances. Always consult with your healthcare provider and insurance plan for the most current requirements and procedures. For personalized assistance with appeals and prior authorization, contact the Washington Office of Insurance Commissioner or consider working with coverage advocacy services.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.